InSite licenses ophthalmic drug delivery device:
This article was originally published in Clinica
Executive Summary
InSite Vision has obtained an exclusive worldwide licence to the University of Rochester's device for the controlled delivery of ophthalmic drugs to the posterior chamber of the eye. The patented device has a needle with an adjustable collar, attached to a curved neck, which is inserted above the eyeball and beneath the upper eyelid. InSite also has an eyedrop-based delivery system, DuraSite, and is developing new diagnostic and therapeutic approaches under its glaucoma genetics programme.
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.